Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation

NCT01817959 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT01817959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01817959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
December 31, 2017
Enrollment
51 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

islet transplantation in diabetes mellitus type 1